You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 28, 2024

LILLY Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for LILLY
International Patents:30
US Patents:1
Tradenames:85
Ingredients:81
NDAs:105

Drugs and US Patents for LILLY

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly CYMBALTA duloxetine hydrochloride CAPSULE, DELAYED REL PELLETS;ORAL 021427-004 Aug 3, 2004 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial
Lilly ALPHALIN vitamin a palmitate CAPSULE;ORAL 080883-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Lilly DROLBAN dromostanolone propionate INJECTABLE;INJECTION 012936-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Lilly PROPYLTHIOURACIL propylthiouracil TABLET;ORAL 006213-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Lilly KEFUROX IN PLASTIC CONTAINER cefuroxime sodium INJECTABLE;INTRAVENOUS 062590-001 Jan 10, 1986 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Lilly ILOSONE erythromycin estolate CAPSULE;ORAL 061897-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Lilly NEBCIN tobramycin sulfate INJECTABLE;INJECTION 062008-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LILLY

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly EVISTA raloxifene hydrochloride TABLET;ORAL 020815-001 Dec 9, 1997 5,641,790 ⤷  Try a Trial
Lilly DECABID indecainide hydrochloride TABLET, EXTENDED RELEASE;ORAL 019693-001 Dec 29, 1989 4,389,393 ⤷  Try a Trial
Lilly ALIMTA pemetrexed disodium POWDER;INTRAVENOUS 021462-002 Sep 7, 2007 5,217,974*PED ⤷  Try a Trial
Lilly CIALIS tadalafil TABLET;ORAL 021368-003 Nov 21, 2003 6,821,975*PED ⤷  Try a Trial
Lilly CIALIS tadalafil TABLET;ORAL 021368-002 Nov 21, 2003 6,943,166*PED ⤷  Try a Trial
Lilly PROZAC fluoxetine hydrochloride SOLUTION;ORAL 020101-001 Apr 24, 1991 4,314,081*PED ⤷  Try a Trial
Lilly SYMBYAX fluoxetine hydrochloride; olanzapine CAPSULE;ORAL 021520-005 Dec 24, 2003 6,960,577 ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for LILLY drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Capsules 40 mg ➤ Subscribe 2012-05-10
➤ Subscribe Capsules 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg and 12 mg/50 mg ➤ Subscribe 2005-01-10
➤ Subscribe For Injection 200 mg/vial ➤ Subscribe 2005-11-01
➤ Subscribe For Injection 2 g/vial ➤ Subscribe 2007-08-24
➤ Subscribe For Injection 500 mg/vial ➤ Subscribe 2008-02-04
➤ Subscribe For Injection 750 mg/vial ➤ Subscribe 2016-10-06
➤ Subscribe Tablets 2.5 mg ➤ Subscribe 2008-10-14
➤ Subscribe Delayed-release Capsules 20 mg, 30 mg and 60 mg ➤ Subscribe 2008-08-04
➤ Subscribe Capsules 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg ➤ Subscribe 2007-05-29
➤ Subscribe Capsules 3 mg/25 mg ➤ Subscribe 2008-05-08
➤ Subscribe For Injection 1g/vial ➤ Subscribe 2005-11-14
➤ Subscribe For Injection 100 mg/vial ➤ Subscribe 2008-07-01
➤ Subscribe For Injection 1000 mg/vial ➤ Subscribe 2012-06-27
➤ Subscribe Injection 250 mcg/mL, 2.4 mL prefilled Pen ➤ Subscribe 2015-07-27
➤ Subscribe Tablets 5 mg, 10 mg and 20 mg ➤ Subscribe 2007-11-21

Supplementary Protection Certificates for LILLY Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0247633 62/1997 Austria ⤷  Try a Trial PRODUCT NAME: ATORVASTATIN CALCIUM; NAT. REGISTRATION NO/DATE: 1-21926, 1-21927, 1-21928 19970411; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107
0122707 SPC/GB95/031 United Kingdom ⤷  Try a Trial PRODUCT NAME: GEMCITABINE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY- ACCEPTABLE SALT; REGISTERED: NL RVG17854 19950327; UK 00006/0301 19951026; UK 00006/0302 19951026
0721777 SPC/GB04/033 United Kingdom ⤷  Try a Trial PRODUCT NAME: ATOMOXETINE, OPTIONALLY IN THE FORM OF A SALT, SUCH AS THE HYDROCHLORIDE; REGISTERED: UK PL 00006/0374 20040527; UK PL 00006/0375 20040527; UK PL 00006/0376 20040527; UK PL 00006/0377 20040527; UK PL 00006/0378 20040527; UK PL 00006/0379 20040527
0740668 PA2003001 Lithuania ⤷  Try a Trial PRODUCT NAME: TADALAFILUM ((6R,12AR)-2,3,6,7,12,12A-HEKSAHIDRO-2-METIL-6-(3,4-METILENDIOKSIFENIL)-PIRAZINO(2',1':6,1)PIRIDO(3,4-B)INDOL-1,4-DIONAS); REGISTRATION NO/DATE: 03/8034/3, 03/8035/3 20030328
3141251 301099 Netherlands ⤷  Try a Trial PRODUCT NAME: A MEDICINAL PRODUCT CONSISTING OF A COMBINATION OF A FIRST DOSE PHARMACEUTICAL COMPOSITION AND A SECOND DOSE PHARMACEUTICAL COMPOSITION, THE FIRST DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, SODIUM SULPHATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE AND THE SECOND DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, ASCORBIC ACID, SODIUM ASCORBATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE; NATIONAL REGISTRATION NO/DATE: RVG 120195 20171114; FIRST REGISTRATION: IS IS/1/17/083/01 20171016
1480644 16C1019 France ⤷  Try a Trial PRODUCT NAME: ASSOCIATION OU MELANGE PHARMACEUTIQUE RENFERMANT EN TANT QU'INGREDIENTS ACTIFS:(1) LA CEFTAZIDIME OU UN DES SES SELS ET (2) L'AVIBACTAM OU UN DE SES SELS; REGISTRATION NO/DATE: EU/1/16/1109 20160628
0273658 2005C/001 Belgium ⤷  Try a Trial PRODUCT NAME: CHLORHYDRATE DE DULOXETINE; REGISTRATION NO/DATE: EU/1/04/280/001 20040811
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.